Objective: This study investigated the impacts of oligomeric proanthocyanidins (OPC) on patient with asthma to develop new therapeutic options for asthma treatment. Methods: A total of 60 non-acute attack patients with asthma who conventionally received budesonide/formoterol inhalation were randomly divided into the placebo, high-, intermediate-and low-dosage OPC groups. The duration of OPC treatment ranged 8 weeks. Asthma control test(ACT) score, eosinophils(EOS) count and pulmonary function were analyzed. Results: A significant decrease of EOS in peripheral blood was observed in the high-dosage group who received OPC treatment after 4 weeks(P<0.05). When the treatment expended up to 8 weeks, an elevated ACT score (P<0.05) and forced expiratory volume in one second to forced vital capacity ratio(FEV1%) as well as a declined EOS count (P<0.05) were found in the high-dosage group, while intermediate-dosage OPC only presented improvements in EOS count and FEV1% (P<0.05). Dosage and intervention duration were positively correlated with ACT score and FEV1% (P<0.05), and negatively correlated with the number of peripheral blood EOS(P<0.05). Conclusion: Our results exhibited a novel profile of OPC as a potent option for airway inflammation relief and ventilation rescue, highlighting a promising role of OPC in asthma management.